Erythropoietin Drugs Market Analysis

Product Type (Biosimilars, First-generation formulation, and Second-generation formulation)

By the end of 2037, biosimilars segment in the erythropoietin drugs market is poised to reach USD 8.8 billion. EPO drugs, which are used primarily to treat anemia associated with CKD, cancer chemotherapy, and other chronic illnesses, have long been dominated by branded biologic products. However, with patents on several of these biologics expiring, biosimilar versions are entering the market, often at lower prices.

The biosimilars are expected to enhance market accessibility by reducing treatment costs, thereby expanding patient access and ultimately driving erythropoietin drugs market growth. Additionally, as more regulatory agencies worldwide establish clear pathways for the approval of biosimilars, particularly in emerging markets, the acceptance and use of EPO biosimilars are likely to increase.

Key players in the industry are also investing in R&D to improve the efficacy and safety of EPO biosimilars, potentially attracting more healthcare providers and patients to adopt these alternatives. Thus, the rising availability and adoption of biosimilars are estimated to significantly contribute to the growth of the global erythropoietin drugs market in the coming years. Major key players have been actively developing biosimilars which are widely adopted due to their affordability compared to traditional biologic treatments. According to the 2022 biosimilar trends report by Amgen, as of Q2 2022, the FDA lists 96 proposed biosimilar products enrolled in the FDA’s Biosimilar Development Program, an increase of more than 70% since October 2015.

Drug Class (Epoetin-alfa, Epoetin-beta, and Darbepoetin-alfa)

By drug class, the epoetin-alfa segment in erythropoietin drugs market is poised to increase its revenue share by 2037. The growth can be attributed to the increased demand for treatments addressing chronic CKD-related anemia and cancer-associated anemia. Epoetin-alfa, a synthetic form of erythropoietin, has become widely adopted due to its efficacy in stimulating red blood cell production, which is essential for patients.

Moreover, aging population and the rise in chronic diseases, especially CKD, are increasing the demand for epoetin-alfa. As the prevalence of these conditions grows, so does the need for effective anemia treatments, positioning epoetin-alfa as a critical segment driving the erythropoietin drugs market.

Our in-depth analysis of the erythropoietin drugs market includes the following segments: